Pathogenic Neisseria bacteria naturally liberate outer membrane "blebs," which are presumed to contribute to pathology, and the detergent-extracted outer membrane vesicles (OMVs) from Neisseria meningitidis are currently employed as meningococcal vaccines in humans. While the composition of these vesicles reflects the bacteria from which they are derived, the functions of many of their constituent proteins remain unexplored. The neisserial colony opacity-associated Opa proteins function as adhesins, the majority of which mediate bacterial attachment to human carcinoembryonic antigen-related cellular adhesion molecules (CEACAMs). Herein, we demonstrate that the Opa proteins within OMV preparations retain the capacity to bind the immunoreceptor tyrosine-based inhibitory motif-containing coinhibitory receptor CEACAM1. When CD4 ؉ T lymphocytes were exposed to OMVs from Opa-expressing bacteria, their activation and proliferation in response to a variety of stimuli were effectively halted. This potent immunosuppressive effect suggests that localized infection will generate a "zone of inhibition" resulting from the diffusion of membrane blebs into the surrounding tissues. Moreover, it demonstrates that OMV-based vaccines must be developed from strains that lack CEACAM1-binding Opa variants.
The Neisseriaceae include the bacteria that cause invasive meningococcal disease and the sexually transmitted infection gonorrhea as well as several nonpathogenic commensals of the nasopharyngeal mucosa. The commensal species undoubtedly contribute to the evolutionary success of neisserial pathogens, as the natural competence of the Neisseriaceae for genetic transformation enables frequent exchange of genetic information between colocalized populations (14) . As such, neisserial virulence factors are subject to frequent antigenic variation as new sequences are acquired from other strains (10) . However, the interspecies similarities that result from this genetic exchange may also contribute to the development of acquired immunity against Neisseria meningitidis, since Neisseria lactamica colonization of the nasopharynx is associated with the appearance of bactericidal antimeningococcal antibodies (15) and significant protection from meningococcal disease (35) .
Regardless of the species, Neisseria bacteria attach to the apical surfaces of mucosal epithelial cells via their pili (23) . Retraction of this fibrillar organelle (29) allows tight secondary binding by one of a variety of integral outer membrane proteins to apically expressed host cellular receptors (12, 16) . Of these, phase-variable colony opacity-associated (Opa) proteinmediated binding to human carcinoembryonic antigen-related cellular adhesion molecules (CEACAMs) has been shown to mediate neisserial entry (18) and transcellular transcytosis across polarized epithelial monolayers (49) so that they may access the subepithelial space (28) . While other virulence factors undoubtedly contribute to the colonization process, the exquisite specificity of Neisseria for CEACAM proteins derived from humans has hampered attempts to define their relative contributions in vivo.
Effective vaccines based upon capsular polysaccharide offer serogroup-specific protection against meningococci of serogroups A, C, Y, and W135, but serogroup B polysaccharide is poorly immunogenic (30) , and alternative vaccination strategies are required. The abilities of meningococci to switch capsular types (48) indicate that effective serogroup-specific vaccination may simply induce selection of capsular types unrecognized by vaccine-derived responses. This indicates the need for a vaccine protective against all virulent meningococci. While numerous protein candidates are being considered, the remarkable antigenic variation of neisserial surface antigens has so far precluded success. To overcome this challenge, surface antigens have been presented in the context of outer membrane vesicles (OMVs), the compositions of which reflect those of the strains from which they are derived (13, 37, 40) . Curiously, Neisseria bacteria shed such blebs of outer membrane during both in vitro growth and in vivo infection (32, 37) , yet their contribution to virulence remains unknown. OMVs derived from N. lactamica can elicit cross-reactive and protective immunological responses against diverse meningococcal strains in a mouse model of infection (34) . N. lactamica OMV (Nl-OMV)-based vaccines have the theoretical benefit of targeting antigens conserved between different neisserial species, thereby increasing the likelihood of conservation among all meningococcal strains. For example, the absence of PorA protein in N. lactamica (24) is likely to negate problems associated with the variation of this immunodominant but serosubtypespecific antigen.
Opa proteins are a major component of the outer membranes of both pathogenic and commensal neisserial species (44) . Given their expression in vivo (22, 43) and contribution to neisserial virulence (39) , the Opa proteins would seem an important component of any Neisseria-specific vaccine. However, we have observed that binding of gonococcal Opa protein to the human coinhibitory receptor CEACAM1 suppresses the activation and proliferation of CD4 ϩ T lymphocytes (5). This effect is determined by recruitment of the tyrosine phosphatases SHP-1 and SHP-2 to a functional immunoreceptor tyrosine-based inhibitory motif (ITIM) within the CEACAM1 cytoplasmic domain (5, 7, 8, 17, 21, 31) . Since CD4 ϩ T cells govern the development of specific immunity, such an effect would undoubtedly curtail the adaptive immune response to natural infection. In this study, we demonstrate that Opa proteins retain CEACAM-binding function in the context of OMVs derived from both Neisseria gonorrhoeae and N. meningitidis and that this interaction potently inhibits human CD4 ϩ T-lymphocyte activation and proliferative responses.
MATERIALS AND METHODS

Cell lines and tissue culture techniques. Primary human CD4
ϩ T cells were negatively selected from peripheral blood mononuclear cells by using the EasySep immunomagnetic-based cell purification system (Stemcell Technologies, Vancouver, British Columbia). Purified primary lymphocytes and the Jurkat CD4 ϩ human T-lymphocyte line (ATCC CRL-10915) were both maintained in RPMI 1640 medium (Invitrogen Life Technologies, Burlington, Ontario) supplemented with 10% heat-inactivated fetal bovine serum and 4 mM GlutaMAX (Invitrogen), referred to as RPMI-G. Cells were cultured at 37°C in 5% CO 2 humidified air. Where indicated, the CD4 ϩ T cells were stimulated with the indicated concentrations of recombinant human interleukin-2 (IL-2; BD Pharmingen, Mississauga, Ontario) for 48 h prior to antibody or OMV challenge. COS-7 African green monkey kidney cells (ATCC CLR-1651) were maintained in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (Cansera; Etobicoke, Ontario), 100 units/ml penicillin-streptomycin, 1 mM GlutaMAX, 1 mM sodium pyruvate, and 1 mM nonessential amino acids (Invitrogen). Cells were cultured as described above.
Bacterial strains. N. meningitidis strain K454 (26) and N. lactamica Y92 1009 (34) were obtained from the Meningococcal Reference Unit, Manchester, United Kingdom. Neisseria gonorrhoeae MS11-derived strains constitutively expressing defined Opa variants (25) were generously provided by T. F. Meyer (Max-Planck-Institut für Infektionsbiologie, Berlin, Germany). Opa variants were expressed in the background of MS11 strain N279, which does not express pilin and has a deletion in the opaC 30 locus encoding this strain's only heparan sulfate proteoglycan (HSPG) receptor-specific Opa variant (25) . N. meningitidis and N. lactamica were grown from frozen stocks on brain heart infusion agar plus 1% (vol/vol) horse serum (Difco Laboratories, West Molesey, Surrey, United Kingdom), and N. gonorrhoeae strains were grown from frozen stocks on GC agar (Difco, Oakville, Ontario) supplemented with 1% (vol/vol) IsoVitaleX enrichment (BBL; Becton Dickinson, Cockeysville, MD). All bacterial strains were cultured at 37°C in 5% CO 2 humidified air, and gonococcal strains were subcultured daily, using a binocular microscope to maintain the desired opacity phenotype. Opa expression and variant type were routinely confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (10%), with resolved proteins either stained using Coomassie brilliant blue or subjected to immunoblot analysis using the Opa cross-specific monoclonal antibody 4B12/C11 (2), which was generously provided by M. Achtman (Max-Planck-Insitut für Infektionsbiologie, Berlin, Germany).
Preparation and physical characterization of OMVs. OMVs were prepared from N. meningitidis and N. lactamica isolates essentially as described previously (41) . Briefly, overnight liquid cultures were prepared in Franz medium, and bacteria were pelleted by centrifugation at 1,000 ϫ g. Bacterial pellets were resuspended in OMV buffer containing 0.15 M NaCl, 0.05 M Tris-HCl, and 0.01 M EDTA (pH 7.5) and then heated to 56°C for 30 min before being sheared in a Wearing blender for 3 min. The resultant extract was centrifuged at 25,000 ϫ g for 20 min, and the supernatant was retained. The pellet was washed, and the supernatant was again retained. These supernatants were pooled and clarified by centrifugation at 25,000 ϫ g for 20 min and then were centrifuged at 100,000 ϫ g for 2 h. The final OMV-containing pellet was washed twice, resuspended in phosphate-buffered saline (PBS), and stored at Ϫ80°C.
Gonococcal OMVs were prepared from recombinant gonococcal strains (25) with defined Opa phenotypes and receptor specificities (19) . Bacteria were passaged overnight on solid medium (as described above). Near-stationary-phase liquid cultures were prepared by resuspension in modified brain heart infusion (Difco) containing 10 mM LiCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 50 mM HEPES, and 1% (wt/vol) D-glucose (pH 7.2) and then incubation at 37°C in 5% CO 2 humidified air with rapid shaking. Thereafter, the cultures were incubated for a further 2 h at 40°C with rapid shaking. Bacteria were removed by centrifugation at 1,000 ϫ g for 20 min and resuspended in PBS containing 0.05% (wt/vol) sarkosyl (Bioshop Canada, Inc., Burlington, Ontario) and 0.05% (wt/vol) sodium deoxycholate (Bioshop). Resuspended cells were incubated at 56°C for 30 min with gentle mixing and then chilled on ice. These bacterial suspensions were extracted using a Wheaton homogenizer and then sonicated on ice (five 10-s pulses). Extracts were clarified by centrifugation at 25,000 ϫ g for 20 min, and the resulting supernatant was centrifuged at 100,000 ϫ g for 2 h. The final pellet, which contained OMVs, was washed twice, resuspended in PBS, extruded through a 0.22-m syringe filter, and then stored at Ϫ80°C. OMVs isolated using this protocol have been analyzed by electron microscopy and negative staining (Nl-OMVs and N. meningitidis OMVs [Nm-OMVs]) or by comparative flow cytometric analysis (N. gonorrhoeae OMVs), with no discernible difference in size distribution evident between strains. In some experiments, OMVs were labeled using fluorescein isothiocyanate (FITC; Sigma) according to the manufacturer's specifications.
Construction and expression of CEACAM1-Fc fusion proteins. An expression vector encoding the extracellular domains of CEACAM1 fused to the Fc portion of human immunoglobulin G1 (IgG1) was previously described (50) . Recombinant CEACAM1-Fc protein was expressed in COS-7 cells following transient transfection using FuGENE6 reagent (Roche Molecular Biochemicals, Indianapolis, IN) according to the manufacturer's specifications. Cell culture supernatant was harvested 48 to 72 h after transfection and was clarified by centrifugation at 1,000 ϫ g for 20 min at 4°C. The clarified supernatant was filtered using a vacuum-driven disposable filtration system (Stericup 0.22 m; Millipore, Nepean, Ontario) and concentrated using a 10-kDa-cutoff polyethersulfone ultrafiltration concentrator (Millipore). The fusion protein was then purified by binding to protein A-Sepharose (Sigma) and the bound protein eluted using 0.2 M glycine-HCl (pH 2.5), with aliquots recovered directly into collection tubes containing 100 l 1 M Tris (pH 9.0) to neutralize the samples. Purified eluate was dialyzed against PBS at 4°C and then concentrated to less than 1 ml with Ultrafree Biomax centrifugal filters (Millipore). The appropriate functions of the resulting CEACAM1-Fc preparations were confirmed by their specific binding to isogenic gonococcal strains expressing defined Opa protein variants (data not shown).
Determination of Opa binding function. Interactions between OMV preparations containing defined Opa variants and CEACAM1 were quantified by an enzyme-lined immunosorbent assay (ELISA). Initially, the protein content of each OMV preparation was determined using the bicinchoninic acid assay system (Pierce Chemical Company, Rockford, IL), and samples containing equal amounts of total protein were immobilized on 96-well microtiter plates (Corning Corporation, Midland, MI). Each OMV was applied in triplicate serial doubling dilutions and then exposed to a standard concentration of the CEACAM1-Fc fusion protein. Bound CEACAM1-Fc was quantified using protein A-conjugated horseradish peroxidase and the o-phenylenediamine dihydrochloride colorimetric system (Sigma), with spectrophotometric analysis at 450 nm. A Student t test analysis was performed on the data to determine the statistical significance of differences in CEACAM1-Fc binding by different OMV preparations.
Flow cytometric analyses. Association between FITC-labeled OMVs and IL-2 prestimulated lymphocytes was assessed by flow cytometric analysis. Where indicated, T-cell activation was assessed by quantifying the expression of the well-characterized T-cell activation marker CD69 by using the allophycocyaninconjugated monoclonal antibody FN50 (Pharmacia, Mississauga, Ontario) 16 h after exposure to the activating stimuli. Analysis of lymphocyte proliferation. The CD4 ϩ T lymphocytes were routinely cultured in the presence of 1,000 units/ml of recombinant human IL-2 (BD Pharmingen) to induce CEACAM1 expression. Primary CD4 ϩ T cells were further activated by coligation of the T-cell receptor (CD3) and CD28, using 1 g/ml mouse anti-human CD3ε-specific monoclonal antibody (clone UCHT1; BD Pharmingen) and 1 g/ml mouse anti-human CD28 monoclonal antibody (clone CD28.2; BD Pharmingen) followed by 3 g/ml Fab 2 fragments of goat anti-mouse IgG (Jackson Immunoresearch Laboratories, West Grove, PA). Jurkat cell stimulation via the T-cell receptor was induced by exposure to the CD3ε-specific monoclonal antibody UCHT1 followed by the goat anti-mouse IgG cross-linker. Parallel, density-matched suspensions containing 3 ϫ 10 5
CD4
ϩ T cells, as assessed by direct counting with a Levy double hemocytometer, were treated in RPMI-G with either CEACAM-specific antibody (anti-CEA; DAKO Diagnostics, Mississauga, Ontario), a nonreactive control antibody (DAKO Diagnostics), or OMVs at the indicated concentrations. Two hours after the commencement of infection, gentamicin (Bioshop, Burlington, Ontario) was added to obtain a final concentration of 100 g/ml to prevent bacterial overgrowth. CD4
ϩ T-cell culture densities were determined by direct counting using a Levy double hemocytometer at the indicated times. In each instance, proliferation was assessed using a standardized counting pattern and no fewer than six fields, each containing 10 to 100 cells. A Student t test analysis was performed on the data to determine if statistically significant differences exist between NlOMVs and Nm-OMVs or isotype antibody and anti-CEACAM1 antibody on T-cell proliferation for each time point. All experiments were performed on a minimum of three separate occasions.
RESULTS
Opa protein function in the context of OMVs. Pathogenic (N. meningitidis) (Fig. 1A) and commensal (N. lactamica) (Fig.   1B ) Neisseria spp. naturally overproduce and evaginate the outer membrane in the form of vesicles (OMVs) or "blebs" (32, 37) . To test whether Opa proteins within OMVs retain their CEACAM-binding function, experimental vaccines were prepared. These typically contained vesicles of 100 Ϯ 20 nm in diameter (data not shown), and consistent with previous work (33) , the presence of Opa proteins reflected that of the outer membranes of the bacteria from which they were derived (Fig.  1C) . To specifically ascribe differences in OMV binding function rather than other strain-related differences to expressed Opa variants, control OMVs that express the well-defined Opa 50 (which binds HSPG) (Opa HSPG ) or Opa 52 (which binds CEACAM1) (Opa CCM ) protein or no Opa protein (Opa Ϫ ) were prepared from isogenic strains of N. gonorrhoeae (19) .
Soluble chimeras consisting of the extracellular portion of human CEACAM1 fused to the Ig Fc domain (CEACAM1-Fc) were used to determine if Opa proteins retain their abilities to bind CEACAM1 family receptors when in the context of OMVs. Equal amounts of each OMV preparation were exposed to soluble CEACAM1-Fc fusion protein in an ELISA. The relative levels of CEACAM1 binding by N. gonorrhoeaederived Opa HSPG and N. lactamica-derived OMVs were not significantly different from that by OMVs derived from Opa Ϫ bacteria; however, each of these remained a small fraction of that seen with OMVs derived from our control strain expressing an Opa variant that binds to CEACAM1 (Opa CCM ) or the Opa ϩ N. meningitidis variant (Fig. 1D) . 
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To confirm that this binding function allowed vesicle association with CEACAM1-expressing cells, OMVs prepared from the recombinant N. gonorrhoeae strains expressing defined Opa variants were labeled with FITC. These were incubated with IL-2-prestimulated CD4 ϩ T lymphocytes, which were then analyzed by flow cytometry. The HSPG-specific Opa variant conferred a fivefold-increased association of the OMVs with the T cells compared to Opa-deficient OMVs, while the CEACAM-specific Opa variants displayed an even more pronounced (100-fold) increase in binding (Fig. 1E) . When combined, these results demonstrate that Opa CCM proteins retain their abilities to bind CEACAM1 when in the context of an OMV.
Meningococcal OMVs inhibit T-cell proliferation. Given that Nl-OMVs differed from Nm-OMVs with respect to Opa phenotype (Fig. 1C) and CEACAM1 binding (Fig. 1D) , we tested whether there was a difference in lymphocyte response to these vaccine preparations. The meningococcal OMVs caused a dose-dependent reduction in CD4 ϩ T-cell proliferation in response to ligation of the T-cell receptor with the costimulatory molecule CD28, apparent as both a delay in the onset of cell culture expansion and a slower increase in cell number over time (Fig. 2A) . Consistent with their lacking Opa proteins, the N. lactamica-derived OMVs had no similar effect (Fig. 2A) . The reduction in CD4 ϩ T-cell proliferation in the presence of Nm-OMV could result from either an increase in cell death or a reduction in the rate of proliferation. At 120 h, there was no difference in annexin V-FITC staining of cultures administered the various antibody or OMV preparations (90.9% Ϯ 1.88% between all samples; data not shown), consistent with the Nm-OMV-inhibiting T-cell proliferation. As in our previous study (5) , polyclonal CEACAM-specific antisera displayed an inhibitory effect reminiscent of the Opa-containing OMVs (Fig. 2B) , consistent with CEACAM1 ligation being sufficient to inhibit expansion of the T-cell population.
CEACAM1-binding Opa proteins confer the lymphocyte inhibitory effect. Given that species-related differences in constitutive and phase-variable virulence factors other than Opa could be responsible for the differential effects of Nm-and Nl-OMVs on T-cell proliferation, we compared the effects of OMVs isolated from our well-defined isogenic strains of N. gonorrhoeae that express distinct Opa phenotypes. As with the intact bacteria (5), OMVs containing the CEACAM1-specific Opa CCM protein caused a marked reduction in T-cell proliferation relative to cells that have been exposed to OMVs containing either no Opa protein or the Opa HSPG protein (Fig.  3A) . The CEACAM1-specific OMVs also effectively inhibit T-cell expression of the immediate-early activation marker CD69 (27, 46) , indicating a block early in the normal response of the cells to activating stimuli. Exposure to gonococcal OMVs demonstrated that CEACAM1-binding Opa proteins showed a similar block in T-cell activation and CD69 expression 16 h after T-cell activation (Fig. 3B) . Combined, these results establish that Opa variants within OMVs retain their abilities to bind CEACAM1 and effectively inhibit T-cell activation by a CEACAM1-dependent mechanism. on October 1, 2017 by guest http://iai.asm.org/ DISCUSSION The Neisseriaceae are known to produce OMVs or "blebs" (Fig. 1) during the course of natural infection (6, 32, 37, 38) ; however, their function and contribution to pathogenesis have remained largely unexplored. Herein, we demonstrate that the Opa proteins retain host CEACAM receptor binding function in the context of OMVs. This activity could undoubtedly confer a cellular tropism to the OMVs, allowing binding to and internalization by CEACAM-expressing human cells. In the context of bacteria adhering to the apical surfaces of epithelial cells, this activity should allow the effective delivery of OMVs to the subepithelial space, since CEACAM-specific Opa expression is itself sufficient to facilitate the transcellular transcytosis of intact bacteria across polarized epithelial cells (49) . As OMVs accumulate in the tissues, both through transcytotic delivery and by liberation from bacteria that have already entered the subepithelial space (28), they should infiltrate tissues more effectively than intact Neisseria bacteria. Considering the potent capacities of CEACAM1-specific vesicles to inhibit T lymphocytes established in this study, it is enticing to speculate that these vesicles would dampen immune cell activation even distal to the site of infection. The coinhibitory effect of CEACAM1 results from its capacity to recruit and activate tyrosine phosphatases SHP-1 and SHP-2, which oppose kinasedependent activating signals (5, 7, 8, 17, 21, 31) . That this function should be conserved in other cell types (17) may explain how these bacteria persist in tissues that should be protected by resident leukocytes. In addition to contributing to virulence, the immune inhibitory effect of CEACAM1-binding OMVs has important implications for ongoing OMV-based vaccine efforts. While polysaccharide capsule-based vaccines are available to protect against some serotypes of N. meningitidis (20) , the inability to generate an adaptive response to the serogroup B capsule has led to the implementation of OMV-based strategies to combat localized epidemics caused by these strains (11, 36, 42) . OMVbased vaccines possess inherent benefits, including that (i) antigens are expressed in the context of the neisserial membrane, allowing the immune response to preferentially target surface-exposed epitopes in their native conformations; (ii) the inclusion of multiple antigens clearly reduces the likelihood that the meningococci's propensity to undergo phase and antigenic variation will result in the simultaneous loss of all epitopes targeted by the protective immune response; (iii) the vaccine should afford protection by a cooperative effect of the responses to multiple antigens, each of which may be insufficient to confer immunity when administered alone; and (iv) lipooligosaccharide functions as an effective adjuvant. Meningococcal OMV-based vaccines have been shown to induce high levels of strain-specific serum and mucosal antibodies in both mice (9, 41) and humans (1) . In mice, the protective efficacies of meningococcal OMVs to challenge by heterologous strains are impressive (34) ; however, such cross-protection is less apparent in human trials, and OMV-based vaccines typically confer little protection on children younger than 4 years of age (4, 11, 45) . While the reason for this difference remains to be explored, it is important to consider that clinical isolates of both pathogenic and commensal Neisseria typically express CEACAM1-binding function (44, 47) . Moreover, the exquisite specificity of neisserial Opa proteins for the human species of CEACAM precludes the immunosuppressive effect of the Opa proteins from being detected in animal models typically used to assess vaccine efficacy.
OMVs are present in vivo and are thought to contribute to the acute pathology of meningococcal septicemia (32) . While other outer membrane proteins also undoubtedly retain their natural conformations in the context of OMVs, their function remains largely unexplored. Given that clinical isolates of Neisseria typically express CEACAM1-specific Opa proteins (44, 47) , these adhesins may contribute through either their effect on tissue tropism or their inhibition of CEACAM1-expressing leukocytes. The liberation of Opa-containing OMVs would, therefore, represent an effective means by which to create a "zone of immunosuppression" surrounding the infected site. A similar effect would presumably occur at the site of immunization with an Opa-containing OMV vaccine. Since the remarkable antigenic variability of surface-exposed portions of the Opa proteins (3) precludes the development of antibodies that cross-react against the distinct Opa variants, OMV preparation from Opa-deficient strains must be considered.
